4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9 Purity > 98,5% (HPLC) Pabrik Panengah Lenvatinib Mesylate
Ruifu Kimia Supply Lenvatinib Mesylate panengah Jeung Purity High
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Métil 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Métil 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimétil-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Métil 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Ngaran Kimia | 4-Chloro-7-Methoxyquinoline-6-Carboxamide |
sinonim | 4-Chloro-7-Methoxy-6-Quinolinecarboxamide;Lenvatinib Impurity 12;Lenvatinib Impurity B;Lenvatinib Impurity LFS-B |
Nomer CAS | 417721-36-9 |
Nomer CAT | RF-PI1971 |
Status Saham | Dina Stock, Kapasitas Produksi 50MT / Taun |
Formula Molekul | C11H9ClN2O2 |
Beurat Molekul | 236.65 |
Titik lebur | > 205 ℃ (Dis.) |
Kapadetan | 1,380±0,060 g/cm3 |
merek | Kimia Ruifu |
Barang | spésifikasi |
Penampilan | Pareum-Bodas mun Lampu Konéng Bubuk |
Purity / Métode Analisis | > 98,5% (HPLC) |
Leungitna dina Drying | <0,50% |
Résidu on Ignition | <0,50% |
Total Kotoran | <1,50% |
Proton NMR Spéktrum | Conforms kana Struktur |
Standar tés | Standar Perusahaan |
Pamakéan | Panganteur Lenvatinib Mesylate (CAS: 857890-39-2) |
Bungkusan: Botol, kantong Aluminium foil, 25kg / Karton Drum, atawa nurutkeun sarat customer urang
Kaayaan Panyimpenan:Simpen dina wadah anu disegel dina tempat anu tiis sareng garing;Ngajaga tina cahaya sareng Uap
4-Chloro-7-Methoxyquinoline-6-Carboxamide (CAS: 417721-36-9) utamana dipaké salaku perantara Lenvatinib Mesylate (CAS: 857890-39-2).Dimekarkeun ku Eisai Inc., lenvatinib mesylate mangrupikeun inhibitor reséptor faktor pertumbuhan endothelial vaskular (VEGF) anu gaduh kagiatan ngalawan subtipe VEGF 1, 2, sareng 3 sareng disatujuan ku FDA di 2015 pikeun pengobatan kanker tiroid anu béda-béda anu aya sacara lokal. kumat, métastatik, atanapi kutang sareng henteu ngaréspon kana perlakuan iodin radioaktif.Dina Méi 2016, FDA disatujuan ubar salaku terapi kombinasi sareng everolimus pikeun pengobatan carcinoma sél ginjal canggih.Kusabab VEGF (sareng reséptor faktor pertumbuhan fibroblast, katelah FGFRs) diduga maénkeun peran dina jalur sinyal kardiovaskuler, inhibisi VEGF2R sareng FGFR panginten janten mékanisme di balik efek samping primér lenvatinib mesylate, nyaéta hipertensi.